IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, June 2024

Global Dosage Form (Cardiovascular Drug) Market Forecast 2022-2032

Mr. Nitin Madanwale[1], Kartik Kore[2], Akshay Kumbhar[3], Vaibhav Kumbhar[4], Vishal Lokare[5]
Assistant Professor, Amepurva Forum Nirant Institute of Pharmacy, Solapur, India[1]
Students, Amepurva Forum Nirant Institute of Pharmacy, Solapur, India[2,3,4,5]

Abstract: *The global dosage form market is experiencing significant growth and is expected to continue to expand in the forecast period. As a college professor, it is important to understand the trends and predictions of this market to provide students with up-to-date knowledge of the pharmaceutical industry. In this expert review, we will explore the forecasted growth and factors influencing the global dosage form market.*

Keywords: Cardiovascular, Global, Dosage form, Market

I. INTRODUCTION

Market Overview:

The global dosage form market refers to the market for various forms of pharmaceutical products such as tablets, capsules, syrups, injections, and others. It plays a crucial role in the delivery of medication to patients in a convenient and efficient manner. The market is influenced by factors such as rising healthcare expenditure, increasing demand for generic drugs, technological advancements, and the growing prevalence of chronic diseases.

Key Trends and Forecasts:

Increasing Demand for Generic Drugs: With the rising cost of branded medications, there has been an increased demand for generic drugs, primarily in developing countries. This trend is expected to drive the growth of the global dosage form market, as more pharmaceutical companies focus on manufacturing generic versions of drugs in different dosage forms.

Technological Advancements: The dosage form market is witnessing rapid technological advancements, including the development of novel drug delivery systems such as trans-dermal patches and controlled-release formulations. These advancements enhance patient compliance, reduce dosing frequency, and improve overall treatment outcomes. The integration of digital technologies and smart devices in dosage forms is also gaining traction, allowing for better patient monitoring and personalized medicine.

Growing Prevalence of Chronic Diseases: The global burden of chronic diseases, such as diabetes, cardiovascular diseases, and respiratory disorders, is steadily increasing. This has led to a higher demand for dosage forms that cater specifically to the treatment and management of these conditions. As a result, the market is expected to witness significant growth in injectables, inhalers, and other specialized dosage forms.

Emerging Markets: Developing countries, especially in Asia-Pacific and Latin America, are projected to exhibit substantial growth in the global dosage form market. Factors such as increasing disposable incomes, improving healthcare infrastructure, and the presence of a large patient pool contribute to the market's expansion in these regions. Market players are focusing on expanding their presence and manufacturing capacities in these emerging markets to capitalize on the growing demand.

Introduction

The global dosage form market plays a crucial role in the pharmaceutical industry, as it encompasses various forms of drug delivery systems. Understanding the trends and forecasts in this market is essential for pharmaceutical companies, investors, and policymakers. This literature review aims to provide a comprehensive overview of the global dosage form market forecast, based on the available research findings.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, June 2024

Report Overview

Cardiovascular Drugs The market is expected to reach USD 92.2 billion by 2032, up from USD 81.3 billion in 2022, with a 1.3% CAGR from 2023 to 2032.The cardiovascular drugs market includes a wide range of pharmacological treatments for various cardiovascular disorders, such as angina, heart failure, and arrhythmia. These pharmacotherapy agents regulate cardiac rhythm, lower the risk of heart attacks and strokes, and treat hypertension. In recent years, the introduction of novel drug formulations and cutting-edge technologies has transformed the market landscape.

In order to discover novel drugs and treatment modalities, pharmaceutical companies devote substantial resources to research and development endeavors, as innovation is a top priority in the cardiovascular drugs market. The introduction of ACE inhibitors, beta-blockers, and calcium channel blockers, which have unquestionably revolutionized the treatment of hypertension and cardiac disorders, are among the most notable advances in this field. Recent years have witnessed an escalating emphasis on personalized medicine, a revolutionary approach that involves tailoring treatment plans based on patient's genetic profiles. The cardiovascular drugs market is poised for remarkable growth in the future years due to an aging population, an increase in the prevalence of cardiovascular pathologies, and an escalating demand for personalized medical interventions. In addition, the convergence of technological advances, including remote monitoring devices and artificial intelligence, has the potential to improve patient outcomes and reduce healthcare costs. Pharmaceuticals, biotechnology, and medical device production are just a few of the industries with stakeholders in the cardiovascular drugs market.

Driving factors

Expansion of the Cardiovascular Drug Market

The cardiovascular drugs market is anticipated to expand considerably over the next few years, primarily due to a number of factors, such as the rising prevalence of cardiovascular diseases. Cardiovascular diseases are becoming more prevalent on a global scale as a result of altering lifestyles, poor diets, and a lack of physical activity. The increasing geriatric population also contributes significantly to the growth of the cardiovascular drugs market, as the elderly are more susceptible to developing cardiovascular diseases. Technological Developments Improve Cardiological Drugs Increasing the effectiveness of cardiovascular drugs has been significantly aided by technological advancements in drug development. Understanding cardiovascular diseases better has led to the development of improved drugs that can target specific disease mechanisms, thereby increasing the effectiveness and safety of the medication. Improving healthcare infrastructure in developing economies, coupled with rising healthcare expenditures, is increasing access to cardiovascular drugs.

Cardiovascular Market Driven by Personalized Drugs

The increasing demand for personalized medicine has also been a significant driver of the cardiovascular drugs market. The market for combination therapies is growing due to favorable reimbursement policies and increased adoption. Additionally, there has been a significant focus.

The cardiovascular drugs market may be impacted by regulatory changes. Regulatory agencies are placing a greater emphasis on safety and efficacy standards, resulting in more stringent regulations for drug developers. Several emerging technologies, such as gene therapies, which have shown promise in treating cardiovascular diseases, may have an impact on the cardiovascular drug market.

Emerging Trends Transform Cardio Drugs

New market entrants, price wars, and increased demand for generic drugs may affect the competitiveness of cardiovascular drugs. market. In addition, emerging trends and changes in consumer behavior, such as an increased awareness of a healthful lifestyle, could have a positive impact on the market.

Restraining Factors

Restriction Impacts on Cardiovascular Drugs

Stringent regulatory policies, high drug development costs, cardiovascular drug side effects, increasing availability of alternative therapies, patent expiration, and generic competition have all had a long-term impact on the cardiovascular

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, June 2024

drug market. Recent changes in the development, marketing, and distribution of cardiovascular drugs have been driven by the growing impact of these factors.

Stricter requirements. Restriction on the Cardio Market Strict regulatory policies are a major barrier to the cardiovascular drug market. Cardiovascular drug regulatory policies are strict because the side effects of these drugs can be severe. Before being approved, cardiac drugs must go through extensive clinical trials to prove their efficacy, safety, and quality. The rigorous approval process is time-consuming and costly.

High costs have an effect on drug development.

Several billion dollars are invested in the development of novel drugs. Research and development, clinical trials, patent fees, and marketing all contribute to high costs. Pharmaceutical companies are not always able to produce new drugs at lower costs, despite increasing pressure to do so. This has resulted in higher drug prices, making them difficult for consumers to afford.Side Effects Affect Cardio Sales Some cardiovascular drug side effects are mild and easily managed, while others are severe and potentially fatal.

Growth Opportunity

Increasing Demand for Cardiovascular Medication

The demand for innovative drugs and personalized treatments is increasing as the prevalence of cardiovascular diseases continues to rise globally. Several factors, including the rising demand for combination therapies, the increasing adoption of biologic drugs, the focus on personalized medicine, the rising importance of early diagnosis and treatment, and the rising demand for Cardiovascular drugs in emerging markets are expected to drive significant market growth. Combination therapies are on the rise. Combining drugs with different mechanisms of action can effectively treat cardiovascular diseases. Combination therapies provide synergistic benefits, increased efficacy, and reduced side effects. Combination therapies are becoming increasingly popular due to their effectiveness. synergistic benefits, enhanced efficacy, and decreased adverse effects. In response to this demand and the effectiveness of combination therapy, combination drugs are flooding the market.

Biologics Transform Treatment

Biologic drugs or biologics are a category of pharmaceuticals derived from living organisms or their compounds. Improved efficacy and safety profiles have revolutionized the treatment of cardiovascular diseases. Biologics are especially effective in the treatment of complex and chronic diseases, including heart failure, arrhythmia, and atherosclerosis, among others. With the increasing use of biologics, the cardiovascular drugs market is anticipated to expand. Personalized Medicine in Cardiovascular Care The focus on personalized medicine is increasing, largely as a result of advancements in genomics, proteomics, and other omics sciences Personalized medicine aims to tailor treatment strategies to each patient's unique genetic and biomarker profiles. Personalized medicine has shown enormous promise in the treatment of cardiovascular diseases, with early detection and targeted treatments providing better outcomes while reducing side effects.

Regional Analysis

The North American market dominates due to rising cardiovascular disease rates and aging populations Our results imply that lifestyle modifications, medical breakthroughs, and preventative care can improve heart health in the region. The aging North American population contributes to cardiovascular disease.

High blood pressure, cholesterol, and diabetes raise heart disease risk as people age. Heart disease is expected to rise across North America. Preventative care for heart disease in the elderly is being prioritized. Increased unhealthy lifestyles are another factor. Smoking, poor diets, and inactivity increase heart disease risk. People are making unhealthy choices due to convenience food and screen time. North American healthcare systems are using lifestyle changes and advanced medical technologies in preventative care to address this tendency. To lower heart disease risk, patients receive food and nutrition advice, stress management, and smoking cessation. Robotic heart surgery, implantable cardioverter-defibrillators, and artificial hearts are other heart health technologies. Medical technology allows doctors to provide patients with minimally invasive heart operations and remote monitoring.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, June 2024

Recent Development

- In 2023, The development of mRNA-based therapies for cardiovascular diseases, the achievement of mRNA-based COVID-19 vaccines, and cardiovascular medicine.
- In 2022, Omecamtiv mecarbil, a selective cardiac myosin activator, received FDA approval 2021 and went on sale.
- In 2021, The Development of Sotagliflozin will be a dual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor.
- In 2020, Inclisiran, a novel drug belonging to the class of PCSK9 inhibitors, received approval and became commercially available. This occurred in late 2019; the drug gained approval in 2020.
- In 2019, Entresto, a combination drug containing sacubitril and valsartan, gained significant traction after receiving approval in 2015

II. CONCLUSION

This literature review provides a comprehensive overview of the global dosage form market forecast, based on the available research findings. While several studies directly relate to the dosage form market, others highlight the importance of sustainability, technology, and external factors in pharmaceutical industries. The gaps in the existing research point towards the need for future studies that explore the integration of sustainable practices, the impact of external factors, and the development of innovative dosage forms to meet evolving needs. By addressing these knowledge gaps, researchers and industry professionals can make informed decisions and contribute to the growth and development of the global dosage form market.

REFERENCES

[1]. Panda, B.., Dey, N. S.., & Rao, M.. (2012). Development of Innovative Orally Fast Disintegrating Film Dosage Forms: A Review. . http://doi.org/10.37285/ijpsn.2012.5.2.2

[2]. Nyol, Sandeep., & Gupta, M. M.. (2013). IMMEDIATE DRUG RELEASE DOSAGE FORM: A REVIEW. Journal of Drug Delivery and Therapeutics

[3]. Gössling, S.. (2021). Tourism, technology and ICT: a critical review of affordances and concessions. Journal of Sustainable Tourism , 29 , 733 750 http://doi.org/10.1080/09669582.2021.1873353

[4]. Salama, M.., Isachenko, V.., Isachenko, E.., Rahimi, G.., Mallmann, P.., Westphal, L.., Inhorn, Marcia C.., & Patrizio, P.. (2018). Cross border reproductive care (CBRC): a growing global phenomenon with multidimensional implications (a systematic and critical review). Journal of Assisted Reproduction and Genetics , 35 , 1277-1288 . http://doi.org/10.1007/s10815-018-1181-x

[5]. Fu, Yunfei., Ma, Yaoming., Zhong, L.., Yang, Yuanjian., Guo, Xuelian., Wang, Chenghai., Xu, Xiaofeng., Yang, Kun., Xu, Xiangde., Liu, Liping., Fan, Guangzhou., Li, Yueqing., & Wang, Donghai. (2020). Land-surface processes and summer- cloud-precipitation characteristics in the Tibetan Plateau and their effects on downstream weather: a review and perspective. National Science Review , 7 , 500 - 515 . http://doi.org/10.1093/nsr/nwz226

[6]. Cardiovascular Drugs Market Drug Class Analysis (Anti-Hypertensive, Anti-Hyperlipidemics, And Others), Distribution Channel Analysis (Hospital Pharmacies, Retail Pharmacies, And Others), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032.

[7]. https://marketresearch.biz/report/cardiovascular-drugs-market/